PremiumThe FlySoros buys Okta, cuts Amazon in Q1 CERE Earnings Report this Week: Is It a Buy, Ahead of Earnings? Cerevel Therapeutics’ tavapadon meets Phase 3 primary endpoint in Parkinson’s PremiumThe FlyNeumora Therapeutics appoints Panandiker as Chief Commercial Officer Cerevel Therapeutics price target raised to $45 from $25 at JPMorgan Karuna downgraded, Arm target raised: Wall Street’s top analyst calls PremiumThe FlyCerevel Therapeutics just downgraded at Stifel, here’s why The biopharma stocks to own in 2024, according to Morgan Stanley The biopharma stocks to own in 2024, according to Morgan Stanley 
